Hair loss sufferers spend billions of Euros a year on hair loss treatments. Unfortunately, a good percentage of the products being marketed are completely ineffective for the majority of those who use them. The psychological and social implications of hair loss can be extremely distressing for the patient, thus establishing a level of vulnerability when it comes to hair loss treatments.
During the last 10 years, medicine has made great strides in the treatment of male hair loss. With the introduction of 5-alpha-reductase inhibitors such as “Propecia” and the evolution of hair restoration, specifically FUE procedures, hair loss is no longer something that is inevitable. With modern medicine, the progression of hair loss can be slowed, and FUE surgery can provide the hair transplant patient with natural looking results.
The following non-surgical hair loss treatments have been approved by the FDA for their effectiveness:
Finasteride is the generic name for Propecia. It was originally developed to treat enlarged prostate glands but soon it was discovered that a side effect was hair growth. In December 1997 the FDA approved finasteride for the treatment of androgenic alopecia in men (male pattern baldness). Finasteride's success is due to its ability to specifically inhibit Type II 5-alpha-reductace, the enzyme that converts testosterone into a more potent androgen dihydrotestosterone (DHT). Propecia can effectively lower DHT levels by as much as 60% when taken daily. It is DHT that shrinks or miniaturizes the hair follicle, which eventually leads to baldness.
Minoxidil was the first drug approved by the FDA for the treatment of male pattern baldness. While Minoxidil has been clinically proven to slow the progression of hair loss and regrow some hair, most hair restoration experts informed see it as a marginally effective drug. Since Minoxidil has no effect on the hormonal process of hair loss, its positive effects are at temporary.